European Endocrinology Editorial Board member Professor Holst joins us at the ADA annual meeting in San Francisco to discuss his current research and the most important current findings in incretin hormones and diabetes.
Filmed at the American Diabetes Association (ADA) annual meeting 2019, San Francisco, USA.
1. What is the role of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) in glucose metabolism? (0:05)
2. Could you tell us a little about your study on the use of GLP-1 and GIP in appetite reduction in obese individuals? (3:11)
3. What future studies are planned? (6:12)
4. What are you most looking forward to at this year’s ADA meeting? (7:33)
Professor Holst has no conflicts of interest to declare in relation to this video.
touchENDO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Diabetes
Andrew Boulton, IDF 2021: Anticipated Congress Highlights
It was a pleasure to meet with IDF President, Prof. Andrew Boulton (University of Manchester, UK) ahead of this year’s virtual meeting to discuss anticipated congress highlights and the relationship between COVID-19 and diabetes. Questions What do you expect to be the highlights of this year’s IDF Congress? (0:20) What have we learned about the […]
IDF Virtual 2021 – Diabetes Complications and Covid-19
The International Diabetes Federation will organise a Virtual Congress on December 6-11, 2021. It will feature the latest research on diabetes complications and sessions dedicated to COVID-19 and diabetes, the centenary of insulin and the IDF Diabetes Atlas 10th Edition. Discover the Congress at https://idf2021.org
Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!